Information Provided By:
Fly News Breaks for April 10, 2017
TSRO
Apr 10, 2017 | 08:00 EDT
Janney Capital analyst Debjit Chattopadhyay started Tesaro with a Neutral rating and $141 fair value estimate, saying its Zejula drug is "relatively well-positioned" by its broad label but that its commercial potential is fully reflected in the share price.
News For TSRO From the Last 2 Days
There are no results for your query TSRO